Critical Warnings & Restrictions In Canada

Basic Toficalm Information

• INN (International Nonproprietary Name): Tofisopam.
• Brand Names Available In Canada (English): Toficalm (India, tablets 50 mg, 100 mg, Torrent Pharmaceuticals; Apple Pharma), Tofisign (India, 100 mg, A M Overseas), Tofifresh (India, 100 mg), Tofiso (India, 50 mg, Apple Pharmaceuticals), TOFIZIN (India, 50 mg, 100 mg, Neuracle Lifesciences), Nextril (India, 100 mg, Torrent Pharmaceuticals), Tofypeace (India, 50 mg, Psychocare Health Pvt. Ltd.), Emandaxin (Europe, 50 mg, 100 mg), Grandaxin (Europe, 50 mg, 100 mg, Egis).
• ATC Code: N05BA23.
• Forms & Dosages: Tablet; strengths 50 mg and 100 mg; common packaging blisters/boxes (10x10 tablets).
• Manufacturers In Canada (English): not specified.
• Registration Status In Canada (English): Not approved by Health Canada; investigational only.
• OTC / Rx Classification: Prescription Only (Rx) in regulated markets.

Overview — Immediate Safety Priorities

Are you worried about ordering a medicine that isn’t approved in Canada?

Tofisopam (INN) is not approved by Health Canada and therefore has no Canadian Drug Identification Number (DIN).

Provincial formularies do not list Toficalm or other tofisopam products for routine coverage.

Patients must not self-import prescription medicines without consulting a clinician or pharmacist.

Importation rules and personal‑use exemptions vary by the Canada Border Services Agency and provincial regulations.

Seek a local prescription for an approved alternative and report adverse reactions to Health Canada’s Canada Vigilance Program.

• Absolute Contraindications: Known hypersensitivity to tofisopam or formulation components.
• Absolute Contraindications: Severe respiratory insufficiency.
• Absolute Contraindications: Sleep apnea syndrome.
• Absolute Contraindications: Acute intoxication with alcohol or other CNS depressants.
• Absolute Contraindications: Severe hepatic impairment.

Checklist — Emergency Signs Requiring Urgent Care:

• Respiratory depression or very slow breathing.
• Severe drowsiness leading to inability to wake.
• New confusion, disorientation, or loss of consciousness.

High‑Risk Groups

Who should be extra careful?

Elderly patients often have increased sensitivity to sedative effects and higher fall risk when combined with other depressant medicines such as diazepam or lorazepam.

Pregnancy and lactation warrant caution; non‑pharmacologic care is preferred first.

For Indigenous patients, prioritise culturally safe, shared decision‑making and consider higher baseline rates of comorbidity and substance‑use when planning therapy.

Interaction With Activities

Can this affect your ability to work or drive?

Tofisopam can cause drowsiness and slowed reaction time, and central nervous system effects are still possible despite a different benzodiazepine subclass.

Avoid driving, operating heavy machinery, or performing safety‑sensitive work until the individual response is known.

Employers may require reporting if impairment affects workplace safety.

Q&A — “Can I Drive After Taking It In Canada?”

Short answer: No reliable evidence supports safety for driving.

Assume impairment is possible (drowsiness, slowed reaction) and do not drive or operate heavy machinery until effects are known.

Consult a pharmacist or prescriber for personalised advice.

Usage Basics For Canadians

INN, Brand Names And Availability

Are you wondering what toficalm actually is and where it comes from?

INN: Tofisopam.

Common brand in India: Toficalm available as 50 mg and 100 mg tablets from Torrent Pharmaceuticals and Apple Pharma.

Other international brands include Grandaxin (Europe), Tofisign, Tofiso, Nextril and Emandaxin.

None of these brands have Health Canada approval and they are prescription‑only in regulated markets.

Legal Classification Under Health Canada

What does it mean that tofisopam is not approved?

DIN

A Canadian Drug Identification Number required for marketed drugs in Canada; tofisopam has no DIN.

INN

International Nonproprietary Name; INN for this product is tofisopam.

Brand

Manufacturer’s trade name such as Toficalm or Grandaxin; these brands are not licensed for sale in Canada.

Prescription‑Only Status

Tofisopam is classified Rx in regulated markets; it is not a Health Canada‑approved marketed prescription in Canada.

• No label claims are authorized in Canada for tofisopam products.
• No Canadian safety monograph exists for tofisopam.
• Standard provincial formularies will not fund or list tofisopam.

Canadian Dosing Guide

Standard Regimens And Clinical Caution

What doses do people take elsewhere?

Typical adult doses internationally are 50–100 mg two to three times daily for anxiety, adjunctive depression, or alcohol‑withdrawal support.

No Health Canada‑approved dosing exists for tofisopam.

Any use in Canada would be off‑label, investigational or via Special Access Programme or personal importation under prescriber oversight.

Adjustments For Comorbidities

How should dosing change with other health problems?

• Reduce dose for elderly patients and increase slowly from the lowest effective dose.
• Use caution and consider dose reduction in hepatic or renal impairment.
• Avoid use in children as safety and efficacy are not established.
• Coordinate with primary care for patients with diabetes or multiple chronic conditions to watch for polypharmacy issues with agents such as alprazolam or clonazepam.

Q&A — “What If I Miss A Dose Under My Provincial Drug Plan?”

Short answer: Follow the prescriber’s instructions and do not double up doses.

If an imported supply causes scheduling issues, contact your prescriber or pharmacist to arrange a refill or switch to an approved alternative covered by provincial plans such as Ontario Drug Benefit or BC PharmaCare.

Interaction Chart (Canadian Context)

Food, Drinks And Lifestyle Interactions

Can everyday habits make tofisopam more dangerous?

Alcohol potentiation of sedative effects is a major hazard and complete abstinence is advised while taking tofisopam.

Caffeine may blunt anxiolytic effects but will not remove sedative risk.

• Avoid alcohol while taking tofisopam.
• Avoid concurrent cannabis use due to additive sedation and altered cognition.
• Avoid opioid use unless under close medical supervision because of respiratory depression risk.

Common Drug Conflicts

Which medicines increase risk when taken with tofisopam?

Likely interactions include other CNS depressants such as opioids, sedating antidepressants, antipsychotics and first‑generation antihistamines.

Use substantial caution with strong CYP inhibitors or inducers if relevant to the manufacturer’s product — monitor clinical effect closely.

Combining multiple sedatives increases fall risk in the elderly.

User Reports & Trends In Canada

Patient Forum Signals And Limitations

What do Canadians search and say online?

Common searches include “Toficalm 100 mg,” “Tofisopam side effects,” “Toficalm for depression,” and “Grandaxin Europe.”

Many discussions reference overseas suppliers and online pharmacies selling Toficalm or Grandaxin.

Unverified anecdotal reports vary in accuracy and product quality can be inconsistent across suppliers.

Community Pharmacy Feedback

How do pharmacists respond when patients bring these questions?

Typical pharmacist guidance is to advise against unapproved imports, recommend approved DIN alternatives, and encourage medication reconciliation and adverse‑event reporting.

Pharmacies in national chains such as Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu can help source approved alternatives and provide counselling.

• Evaluate online anecdotal claims by checking the source, date, sample size and potential conflicts of interest.
• Ask a pharmacist to confirm laboratory batch data or packaging authenticity before considering an imported product.

Checklist — How To Evaluate An Online Claim:

• Look for peer‑reviewed evidence rather than single anecdotes.
• Check manufacturer and batch information on packaging.
• Confirm whether the supplier requires a prescription and offers quality certificates.

Access & Purchase Options

In‑Store Vs Online Realities In Canada

Is it sold in Canadian retail pharmacies?

Toficalm and other tofisopam brands originate mainly from India and Europe and are not available in Canadian retail pharmacies as licensed products.

Legal pathways for access include a prescriber applying through Health Canada’s Special Access Programme or a clinician documenting compassionate use or inclusion in a clinical trial.

Patients may import a small personal supply under Canada Border Services Agency rules, but that varies and requires medical oversight.

Warn against uncontrolled online purchases without prescription or quality assurance.

In our online pharmacy, toficalm is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

National Pharmacy Chains And Provincial Rules

Who can help locally?

National chains provide counselling and can assist in finding approved alternatives that carry a DIN.

Provincial regulation governs pharmacy importation and dispensing; contact the provincial College of Pharmacists for guidance.

Checklist — Steps Before Buying Overseas:

• Discuss the clinical rationale with your prescriber or pharmacist.
• Explore approved DIN alternatives first.
• If considering import, document clinical rationale and obtain prescriber oversight.
• Consider applying to the Special Access Programme where appropriate.
• Verify product authenticity and keep records of batch/expiry for reporting.
• Report adverse events to Canada Vigilance.

Mechanism & Pharmacology

Patient‑Friendly Explanation

What makes tofisopam different from classic benzodiazepines?

Tofisopam is a 2,3‑benzodiazepine derivative, distinct from classic 1,4‑benzodiazepines such as diazepam or alprazolam.

It has anxiolytic properties and is reported to cause less sedation and muscle relaxation compared with classic benzodiazepines.

Despite differences in chemical class and clinical profile, central nervous system effects and dependence risk remain possible.

Clinical Terms And Monograph References

Where should clinicians look for technical detail?

Clinicians should consult international monographs and primary literature for mechanism, pharmacokinetics and metabolism because no Canadian monograph exists for tofisopam.

Chemical Class

2,3‑benzodiazepine derivative.

ATC Code

N05BA23.

Expected Clinical Effects

Anxiolysis with less sedation than many 1,4‑benzodiazepines, possible adjunctive benefit in depression and alcohol‑withdrawal support.

Typical Adverse Reactions

Drowsiness, nausea, dizziness, headache, fatigue.

Indications & Off‑Label Uses In Canada

Approved Indications Internationally Vs Canadian Reality

What is tofisopam used for outside Canada?

International indications include anxiety (typical 50–100 mg two to three times daily), adjunctive use in depression and off‑label adjunctive use in alcohol withdrawal.

None of these indications are Health Canada‑approved for marketing in Canada.

Canadian use would therefore be off‑label, compassionate use, or accessed via the Special Access Programme under prescriber oversight and informed consent.

Common Off‑Label Practices & Clinician Considerations

How do clinicians manage risk when using it off‑label?

• Minimise treatment duration where possible; internationally short courses of 2–6 weeks are typical for anxiety.
• Plan and document a taper to prevent dependence with longer courses.
• Screen for substance‑use history, psychiatric comorbidity and fall risk before starting.

Checklist — Consent Elements:

• Explain risks, including lack of Health Canada approval and no DIN.
• Discuss approved alternatives and their benefits/risks.
• Outline monitoring plan and reporting obligations.
• Obtain signed informed consent where required by local policy.

Key Clinical Findings

Canadian And International Studies 2022–2025

What does recent evidence say?

International trial data show small to moderate evidence supporting anxiolytic efficacy with lower sedation compared with classic benzodiazepines in some studies.

Robust randomised controlled trial data remain limited and clinicians should consult primary literature and specialist sources for up‑to‑date analyses.

Pharmacovigilance activity continues in Europe and India where the drug is marketed.

Ongoing Health Canada Safety Monitoring

How should clinicians report problems?

Health Canada collects adverse‑event reports and provides guidance when imported or investigational products are used.

Clinicians should report suspected adverse drug reactions to Canada Vigilance even for imported products.

Alternatives Matrix

Comparable Medicines With DIN In Canada

What are approved options in Canada to discuss with a prescriber?

Pros And Cons Checklist

How to decide between tofisopam and approved alternatives?

• Consider efficacy for panic or GAD versus sedation impact on work or driving.
• Assess fall risk and interaction profile with existing medicines such as clonazepam or diazepam.
• Check availability and coverage under provincial plans.
• Prefer approved DIN alternatives when possible to ensure quality and pharmacovigilance.

Common Questions From Canadian Patients

What do patients ask most often?

• Why Not Available In Canada? No Health Canada approval and no DIN.
• Can I Import It? Possible with restrictions; consult your prescriber and pharmacist about CBSA rules and the Special Access Programme.
• Is It Safer Than Diazepam? It has a different profile and may cause less muscle relaxation, but it is not necessarily safer and dependence is still a risk.
• How Do I Report Side Effects? Report suspected adverse reactions to Canada Vigilance.

Quick Action Steps For Patients:

• Stop the medicine and seek urgent care for severe adverse reactions such as respiratory depression.
• Keep your medication list up to date and share it with your pharmacist.
• Consult a community pharmacist at national chains for safe alternatives and counselling.

Coverage & Purchase Comparison Table

Provincial Coverage Snapshot & Patient Costs

Is tofisopam covered by public plans?

Without Health Canada approval and a DIN, tofisopam/Toficalm is not covered by provincial plans such as Ontario Drug Benefit, BC PharmaCare or RAMQ.

Step‑By‑Step Purchase Checklist For Canadian Patients

• Discuss treatment options with your prescriber.
• Consider approved DIN alternatives first.
• If import is considered, document clinical rationale and seek prescriber oversight.
• Apply to Health Canada’s Special Access Programme when appropriate.
• Verify product authenticity and packaging on receipt.
• Report any adverse events to Canada Vigilance.

Registration & Regulation

Health Canada Approval Status And Implications

What does non‑approval mean in practice?

Tofisopam is not approved by Health Canada and therefore has no DIN.

Implications include no licensed product monograph, no authorized marketing and no routine pharmacy distribution in Canada.

Legal avenues for clinical use are the Special Access Programme or clinical trial authorisation under Health Canada rules.

Labelling, Bilingual Requirements And Pharmacovigilance

What labelling and reporting rules apply?

• Imported supplies should have clear labelling and batch information; provincial rules may require bilingual patient information when dispensed.
• Clinicians and pharmacists have an obligation to report adverse events to Canada Vigilance, including for imported products.

Special Access Programme (SAP)

A Health Canada pathway for access to non‑marketed drugs on a case‑by‑case basis.

DIN

Drug Identification Number required for marketed drugs in Canada.

Notice Of Compliance (NOC)

Regulatory approval for a drug to be marketed in Canada; not held for tofisopam.

Storage & Handling

Standard Canadian Household Conditions

How should you store tablets at home?

Store below 25°C (77°F) and protect from moisture.

Keep tablets in the original blister until use and avoid bathroom humidity.

Use lockboxes when there is concern for diversion and keep all medicines out of reach of children.

Transport And Cold‑Chain Considerations

Does importing require special transport?

Tablets do not require cold‑chain but climate‑controlled transport is advised to prevent heat or moisture damage when importing.

Checklist For Patients Receiving Imported Medications:

• Verify packaging integrity on arrival.
• Check expiry date and manufacturer batch number.
• Request a certificate of analysis or quality documentation if available.

Guidelines For Proper Use

Canadian Pharmacist Guidance

What should a pharmacist cover in counselling?

Confirm the prescriber’s rationale and review the patient’s medication history for concurrent CNS depressants.

Counsel on driving and employment safety and set short treatment goals with a clear reassessment and tapering plan.

Document informed consent for off‑label or imported use and report any adverse reactions.

Emphasise cultural safety and shared decision‑making in discussions with Indigenous and diverse patients.

Provincial Health Authority Recommendations

What checks should clinicians complete before prescribing or sourcing?

Check provincial drug formularies and college guidance before dispensing or importing and consider DIN alternatives first.

Final Checklist For Clinicians:

• Baseline liver and renal function tests.
• Fall‑risk assessment and medication reconciliation.
• Pregnancy test when applicable and counselling on breastfeeding risks.
• Substance‑use screening and an agreed follow‑up timeline for reassessment.

Patient Handout Template: clear dosing schedule, activity warnings, storage instructions and contact details for reporting side effects.

Delivery Across Canada (English)